Norepinephrine reuptake inhibitor

Norepinephrine

Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the central nervous system by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal. Norepinephrine ( INN) (abbreviated norepi or NE) or noradrenaline ( BAN) (abbreviated NA or NAd) is a See Chemical synapse for an introduction to concepts and terminology used in this article Norepinephrine ( INN) (abbreviated norepi or NE) or noradrenaline ( BAN) (abbreviated NA or NAd) is a In Vertebrates the central nervous system ( CNS) is the part of the Nervous system which is enclosed in the Meninges. Reuptake, or re-uptake, is the reabsorption of a Neurotransmitter by the Neurotransmitter transporter of a pre-synaptic Neuron after Chemical synapses are specialized junctions through which Neurons signal to each other and to non-neuronal cells such as those in Muscles or Glands The drugs inhibit the class of neurotransmitter transporters known as norepinephrine transporters. Neurotransmitter transporters are Proteins that span Cellular membranes and that serve to carry Neurotransmitters across these membranes and to The Norepinephrine transporter or NET (or noradrenaline transporter (NAT is a Monoamine transporter that transports the Neurotransmitter They have virtually no action at other monoamine transporters. Monoamine transporters are structures in nerve-cell membranes that function as Neurotransmitter transporters transferring Monoamine neurotransmitters

List of NRIs

Atomoxetine (Strattera)
Reboxetine (Edronax)
Viloxazine (Vivalan)
Maprotiline (Ludiomil)
Nortriptyline (Nortrilen)
Bupropion (Wellbutrin) (since Bupropion additionally affects dopamine reuptake, it is also considered a member of the norepinephrine-dopamine reuptake inhibitor, or NDRI, class of drugs. Atomoxetine is a non- Stimulant drug approved for the treatment of Attention-deficit hyperactivity disorder (ADHD Reboxetine is an Antidepressant drug used in the treatment of Clinical depression, Panic disorder and ADD/ADHD, developed by Pharmacia (now Viloxazine (Emovit Vivalan Vivarint Vicilan is a bicyclic antidepressant Morpholine derivative that inhibits the reuptake of Norepinephrine. Maprotiline (sold as Deprilept, Ludiomil, Psymion) is a Tetracyclic antidepressant. Nortriptyline is a second generation Tricyclic antidepressant marketed as the Hydrochloride under the trade names Sensoval, Aventyl, Pamelor Bupropion ( INN, previously known as amfebutamone; sold as Wellbutrin, Zyban, and several other Trade names is an atypical Antidepressant Dopamine is a Hormone and Neurotransmitter occurring in a wide variety of animals including both vertebrates and invertebrates A Norepinephrine-dopamine reuptake inhibitor is a class of drugs that is both Dopamine reuptake inhibitor Norepinephrine reuptake inhibitor )
Radafaxine (A drug related to Bupropion presently in clinical trials)

Strattera is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD. Radafaxine is Drug candidate designated 353162 by GlaxoSmithKline, investigated for treatment of Restless leg syndrome and as an NDRI antidepressant Attention-Deficit Hyperactivity Disorder (ADHD is a neurobehavioral developmental disorder affecting about 3-5% of the world's population Off-label uses include the treatment of depression and anxiety. Off-label use is the practice of prescribing drugs for a purpose outside the scope of the drug's approved label most often concerning the drug's indication. Major depressive disorder, also known as major depression, unipolar depression, unipolar disorder, clinical depression, or simply depression Anxiety disorder is a blanket term covering several different forms of abnormal pathological anxieties Fears and Phobias In clinical usage "fear"

Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.

Radafaxine, a potent metabolite of Bupropion, is currently being developed by GlaxoSmithKline. Radafaxine is Drug candidate designated 353162 by GlaxoSmithKline, investigated for treatment of Restless leg syndrome and as an NDRI antidepressant GlaxoSmithKline plc () is a United Kingdom -based pharmaceutical, biological and Healthcare Company.

List of NRIs

See also